Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Dingman

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|January 2, 2019
Immunogenicity of Protein PharmaceuticalsRobert Dingman, Sathy V Balu-Iyer
Clinical and Translational Science|June 7, 2024
Evinacumab: Mechanism of action, clinical, and translational scienceRobert Dingman, Sébastien Bihorel, Viktoria Gusarova, et al.
Immunological Investigations|March 25, 2020
Biological Function and Immunotherapy Utilizing Phosphatidylserine-based NanoparticlesFiona Y Glassman, Robert Dingman, Helena C Yau, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
Clinical and Translational Science|August 26, 2021
REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamicsMohamed A Kamal, Robert Dingman, Claire Q Wang, et al.
JAMA Dermatology|July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension StudyLisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology|August 7, 2022
REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unitFrederic J de Blay, Alina Gherasim, Nathalie Domis, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2021
Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 studyPhilippe Gevaert, Jarno De Craemer, Natalie De Ruyck, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|January 2, 2019
Immunogenicity of Protein PharmaceuticalsRobert Dingman, Sathy V Balu-Iyer
Clinical and Translational Science|June 7, 2024
Evinacumab: Mechanism of action, clinical, and translational scienceRobert Dingman, Sébastien Bihorel, Viktoria Gusarova, et al.
Immunological Investigations|March 25, 2020
Biological Function and Immunotherapy Utilizing Phosphatidylserine-based NanoparticlesFiona Y Glassman, Robert Dingman, Helena C Yau, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
Clinical and Translational Science|August 26, 2021
REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamicsMohamed A Kamal, Robert Dingman, Claire Q Wang, et al.
JAMA Dermatology|July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension StudyLisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology|August 7, 2022
REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unitFrederic J de Blay, Alina Gherasim, Nathalie Domis, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2021
Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 studyPhilippe Gevaert, Jarno De Craemer, Natalie De Ruyck, et al.
Pageof 1